SCHEMBL2296514

SCHEMBL2296514

COC(CNC(=O)CCC(=O)O)OC

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PHF8 Q9UPP1 5/20 0.42
KDM2A Q9Y2K7 5/20 0.42
KDM4E B2RXH2 3/20 0.42
KDM5C P41229 3/20 0.42
EGLN1 Q9GZT9 3/20 0.42
KDM6B O15054 1/20 0.41
FOLH1 Q04609 1/20 0.41
KDM7A Q6ZMT4 1/20 0.41
HTT P42858 2/20 0.40
TSHR P16473 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ALDH1A1 P00352 3/20 0.36
LMNA P02545 1/20 0.36
ALKBH5 Q6P6C2 1/20 0.36
SUCNR1 Q9BXA5 1/20 0.36
RECQL P46063 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30366355 0.92 MEN1 (0.41) TSHRMEN1KMT2AALDH1A1LMNA
SCHEMBL8179403 0.82 MEN1 (0.37) TSHRMEN1KMT2AALDH1A1RECQL
SCHEMBL19743724 0.80 TLR2 (0.44) KDM4EMEN1KMT2AALDH1A1RECQL
SCHEMBL5666064 0.80 MEN1 (0.37) KDM4ETSHRMEN1KMT2AALDH1A1
SCHEMBL14497219 0.79 MEN1 (0.35) PHF8KDM2AKDM4EKDM5CEGLN1
SCHEMBL6924528 0.78 RECQL (0.42) TSHRMEN1KMT2ARECQL
SCHEMBL29010635 0.77 TSHR (0.43) TSHRMEN1KMT2AALDH1A1RECQL
SCHEMBL18373774 0.77 FAAH (0.55) MEN1KMT2ARECQL
SCHEMBL5572365 0.77 TSHR (0.56) TSHRMEN1KMT2AALDH1A1LMNA
SCHEMBL7094098 0.77 CYP2D6 (0.56) PHF8KDM2AKDM4EKDM5CEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110189253-A1 BIOMATERIAL COMPOSITION AND METHOD WARSAW ORTHOPEDIC, INC. (US) 2011-08-04 US disclosed
EP-1773253-B1 SPINAL DISC NUCLEUS PULPOSUS IMPLANT BIOCURE INC (US) 2010-11-24 EP disclosed
US-7666225-B2 Spinal disc nucleus pulposus implant BIOCURE, INC. 2010-02-23 US disclosed
EP-1773253-A4 SPINAL DISC NUCLEUS PULPOSUS IMPLANT BIOCURE INC (US) 2009-02-18 EP disclosed
EP-1773358-A2 BIOMATERIAL BioCure, Inc. (US) 2007-04-18 EP disclosed
EP-1773253-A2 SPINAL DISC NUCLEUS PULPOSUS IMPLANT BioCure, Inc. (US) 2007-04-18 EP disclosed
WO-2006004941-A2 BIOMATERIAL BIOCURE, INC. (US) 2006-01-12 WO disclosed
WO-2006004940-A2 SPINAL DISC NUCLEUS PULPOSUS IMPLANT BIOCURE, INC. (US) 2006-01-12 WO disclosed
US-20050288789-A1 Spinal disc nucleus pulposus implant BIOCURE, INC. 2005-12-29 US disclosed
US-20050287218-A1 Biomaterial BIOCURE, INC. 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110189253-A1 BIOMATERIAL COMPOSITION AND METHOD ILK, KIT, CAD PHF8 2754/4885KDM2A 569/4885KDM4E 1214/4885
US-20050287218-A1 Biomaterial BMP2, ADM2, BMP1 PHF8 4005/4885KDM2A 2271/4885KDM4E 3586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.